Skip to main content

Aurora Daljit Singh's Form 4 filing

Neumora Therapeutics, Inc. (NMRA) · filed Aug 21, 2026

Accession no.
0001610717-26-000385
Filed
Aug 21, 2026, 7:10 PM ET
Trade date
Aug 20-21, 2026
Filing delay
1 day
Rule 10b5-1 plan
Not checked

This filing lists 9 non-derivative transactions and 6 derivative transactions. Open-market sales total $270.0K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Aurora Daljit SinghCIK 0001793971Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 20, 2026Common StockMOption exerciseAcquired+67,741$0.72+$48,773.52116,491Direct
Aug 20, 2026Common StockSSaleDisposed−67,741$1.51F1−$102,586.9748,750Direct
Aug 20, 2026Common StockMOption exerciseAcquired+21,685$0.72+$15,613.221,685Indirect
Aug 20, 2026Common StockMOption exerciseAcquired+45,026$0.72+$32,418.7266,711Indirect
Aug 20, 2026Common StockSSaleDisposed−66,711$1.51F2−$101,000.450Indirect
Aug 21, 2026Common StockMOption exerciseAcquired+20,553$0.72+$14,798.1669,303Direct
Aug 21, 2026Common StockSSaleDisposed−20,553$1.59F7−$32,779.9848,750Direct
Aug 21, 2026Common StockMOption exerciseAcquired+21,055$0.72+$15,159.621,055Indirect
Aug 21, 2026Common StockSSaleDisposed−21,055$1.60F8−$33,599.570Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 20, 2026Common StockMOption exerciseDisposed−67,741$0.00$0109,527Direct
Aug 20, 2026Common StockMOption exerciseDisposed−45,026$0.00$00Indirect
Aug 20, 2026Common StockMOption exerciseDisposed−21,685$0.00$0115,853Indirect
Aug 20, 2026Common StockAGrant or awardAcquired+200,000$0.00$0200,000Direct
Aug 21, 2026Common StockMOption exerciseDisposed−20,553$0.00$088,974Direct
Aug 21, 2026Common StockMOption exerciseDisposed−21,055$0.00$094,798Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

This transaction was executed in multiple trades at prices ranging from $1.485 to $1.625, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F2

This transaction was executed in multiple trades at prices ranging from $1.48 to $1.6252, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F7

This transaction was executed in multiple trades at prices ranging from $1.51 to $1.6379, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F8

This transaction was executed in multiple trades at prices ranging from $1.51 to $1.6393, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Remarks

Title: Chief Operating and Development Officer

Read the full filing on SEC EDGAR (opens in a new tab)